An observational study in Shoulder Pain and Rotator Cuff Injuries, sponsored by University of Utah. Active, not recruiting at 3 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by University of Utah · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.
Among the 146 studies in Shoulder Pain with a site in United States, this one is the 22nd largest by planned enrollment of the 24 observational ones that give a count, is one of 6 that started in 2024, is one of 24 observational ones, reaches primary completion later than 9 of the 27 other live ones, and was the 125th registered.
738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.
Browse Shoulder Pain studies →21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–45 · Healthy volunteers
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Prisma Health-Upstate · Sites in United States
Ages 21–65 · Women only
Lisa Griffin · Sites in United States
Ages 60+
University of Florida · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 10 · Phase 4 21
First in 2003; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 84 across 135 observational studies indexed under Shoulder Pain.
Median enrollment 50 across the 122 interventional studies, 65 across the 24 observational. Of the 101 that completed or were terminated, 32 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 146 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 2 studies filed under Shoulder Pain — fewer than ten, so there is no comparison to draw.
12 of the studies in Shoulder Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851233Rothman Institute OrthopaedicsPatient Education and Sling Use After Shoulder Surgery | 2026-11-30 |
| NCT06039345University of UtahShoulder RFA Pilot Study | 2026-12 |
| NCT07101250Prisma Health-UpstatePreoperative Acetazolamide | 2026-12-01 |
| NCT03653455Rush University Medical CenterPatient Outcomes Collection: How Can we do Better? | 2026-12-31 |
| NCT07400146Cedars-Sinai Medical CenterBupivacaine With Epinephrine Over Diaphragm in Laparoscopy | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 146 studies in Shoulder Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Through this prospective, single-arm cohort pilot study, we plan to explore the safety and effectiveness of Shoulder Radiofrequency Ablation (SRFA) in patients with non-operative chronic shoulder pain due to shoulder osteoarthritis with or without rotator cuff tears.
This will be one of the first collaborative prospective, single-arm cohort using a standardized selection protocol and comprehensive SRFA protocol to treat chronic, refractory shoulder pain due radiographically confirmed glenohumeral joint OA with or without RTC pain, in patients deemed non-surgical candidates by a board-certified orthopedic shoulder surgeon. Upon completing the proposed research, we expect our contribution to fill the knowledge gap on whether SRFA is a potentially viable treatment option for this patient population. This contribution is expected to be substantial because SRFA may be a safe and effective treatment option for many people suffering shoulder pain and debility who are sub-optimal surgical candidates and have historically either been undertreated to have less than ideal treatments options, including opioid-based pain management in particular.
We will explore the effectiveness of SRFA to reduce chronic shoulder pain in 10 participants who were deemed non-surgical candidates by an orthopedic surgeon and who experienced ≥80% pain relief after a single shoulder joint anesthetic block.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Numerical Rating Scale (NRS) at 1, 3, 6 and 12 months after the SRFA
Pain reduction will be measured by calculating the proportion of participants who experienced ≥50% reduction of their shoulder pain on the Numerical Rating Scale (NRS) at 1, 3, 6 and 12 months after the SRFA.
Time frame: 1, 3, 6 and 12 months
Myotomal strength at 1, 3, 6 and 12 months after SRFA
We will calculate the proportion of participants who experience a minimal clinically important difference (MCID) in shoulder abduction, elbow flexion, wrist extension, elbow extension and hand grip measured by dynamometer after SRFA. We will do this by calculating the proportion of participants who experience ≥20% change (MCID) in myotomal strength at 1, 3, 6 and 12 months after SRFA.
Time frame: 1, 3, 6 and 12 months after SRFA
American Shoulder and Elbow Surgeons Score (ASES) at 1,3, 6 and 12 months after SRFA
We will use the validated American Shoulder and Elbow Surgeons Score (ASES) questionnaire to calculate the proportion of participants who experience an MCID on ASES (defined as a score of ≥ 7) at 1,3, 6 and 12 months after SRFA.
Time frame: 1, 3, 6 and 12 months after SRFA
Patient Global Impression of Change (PGIC) at 1,3, 6 and 12 months after SRFA
We will use the validated Patient Global Impression of Change (PGIC) questionnaire to calculate the proportion of participants who experience an MCID on PGIC (defined as a score of ≥ 5) at 1,3, 6 and 12 months after SRFA.
Time frame: 1, 3, 6 and 12 months after SRFA
Plan to share: No
Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.
Of 49 non-industry observational studies under Shoulder Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 24. This study's planned 34 months is above that.
Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.